Clinical trial / 2019
Icosapent ethyl (4 g/day) significantly reduced the risk of major ischemic cardiovascular events in statin-treated patients with elevated triglycerides.
A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).
- Study type
- Multicenter, randomized, double-blind, placebo-controlled trial
- Who was studied
- 8179 statin-treated patients with established cardiovascular disease or diabetes plus risk factors, and elevated fasting triglycerides
- What was measured
- Composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina
THE PAPER
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. N Engl J Med, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.